Vertex and SpliSense address CF with novel inhaled mRNA approaches
Courtesy of Getty Images Oh, what mRNA can do – is a common refrain this week. On Tuesday, Moderna and Merck announced that their investigational mRNA cancer vaccine improved outcomes in relapse-free survival in advanced melanoma. More quietly on Monday, Vertex announced approval of a new drug application for VX-522, an mRNA therapy designed to …
Vertex and SpliSense address CF with novel inhaled mRNA approaches Read More »